Discontinued — last reported Q1 '20
Pfizer Restructuring Reserve decreased by 7.6% to $1.84B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 13.9%, from $2.13B to $1.84B. Over 4 years (FY 2020 to FY 2024), Restructuring Reserve shows an upward trend with a 27.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests active cost-cutting or strategic realignment, which may lead to future margin expansion but indicates current operational friction.
This liability captures the estimated costs associated with formal restructuring plans, such as severance packages, faci...
Common in large financial institutions undergoing digital transformation or cost-rationalization programs.
restructuring_reserve| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $596.00M | $1.14B | $1.07B | $952.00M | $913.00M | $867.00M | $1.20B | $750.00M | $714.00M | $585.00M | $1.99B | $1.64B | $2.40B | $2.13B | $2.12B | $2.40B | $1.99B | $1.84B |
| QoQ Change | — | +90.4% | -5.6% | -11.1% | -4.1% | -5.0% | +38.9% | -37.7% | -4.8% | -18.1% | +239.8% | -17.6% | +46.5% | -11.1% | -0.6% | +13.2% | -17.2% | -7.6% |
| YoY Change | — | — | — | — | +53.2% | -23.6% | +12.4% | -21.2% | -21.8% | -32.5% | +65.1% | +118.4% | +236.0% | +264.4% | +6.6% | +46.5% | -17.2% | -13.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.